Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gina D Amato

Hematology & Oncology Atlanta, GA Medical Doctor

NPI 1750312195 CMS profile 306518

1100 Johnson Ferry Rd Ne, Suite 600, Atlanta, GA 30342

Open in the dashboard

General payments

$96,736

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,764,090 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Gina D Amato of Atlanta, GA is reported in the CMS Open Payments database as having received $96,736 across 119 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,764,090 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,999 37
2024 General $29,877 36
2023 General $5,565 14
2022 General $4,963 11
2021 General $9,777 7
2020 General $4,403 3
2019 General $8,153 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gina D Amato
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Gina D Amato were reported at $33,999. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Gina D Amato Hematology & Oncology median Middle half National median
2019 $8,153 $529 $121–$2,516 $163
2020 $4,403 $339 $82–$2,213 $114
2021 $9,777 $263 $49–$1,965 $132
2022 $4,963 $416 $103–$2,395 $149
2023 $5,565 $542 $125–$2,646 $160
2024 $29,877 $692 $141–$3,008 $164
2025 $33,999 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Deciphera Pharmaceuticals Inc. $33,552 30 payments
  2. SpringWorks Therapeutics, Inc. $28,732 27 payments
  3. Daiichi Sankyo Inc. $13,349 19 payments
  4. Aadi Bioscience, Inc. $7,997 17 payments
  5. Lilly USA, LLC $6,974 2 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $2,960 1 payment
  7. Bayer HealthCare Pharmaceuticals Inc. $2,362 10 payments
  8. Exelixis Inc. $172 1 payment
  9. Amgen Inc. $128 2 payments
  10. Jazz Pharmaceuticals Inc. $95 1 payment
  11. Other $414 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,420 13 payments
  2. Consulting Fee $32,480 15 payments
  3. Honoraria $15,468 6 payments
  4. Travel and Lodging $5,712 14 payments
  5. Food and Beverage $4,573 70 payments
  6. Education $85 1 payment
Products named General payments · program years 2019–2025
  1. QINLOCK $27,514 22 payments
  2. Turalio $13,138 17 payments
  3. VIMSELTINIB $5,458 7 payments
  4. OGSIVEO $5,048 6 payments
  5. FYARRO Immunosuppressant $4,447 5 payments
  6. Stivarga $2,264 9 payments
  7. Fyarro Cancer $1,001 11 payments
  8. ROMVIMZA $580 1 payment
  9. Vitrakvi $212 6 payments
  10. Vanflyta $211 2 payments
  11. Other $1,192 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

377

Median for Hematology-Oncology: 604

Drug cost

$523,120

Median for Hematology-Oncology: $1,306,514

Branded share of claims

20.2%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pazopanib Hcl Generic 25 $306,316
Tagrisso Osimertinib Mesylate Brand 12 $202,825
Eliquis Apixaban Brand 14 $8,937
Imatinib Mesylate Generic 15 $1,373
Asa-Butalb-Caffeine-Codeine Codeine/Butalbital/Asa/Caffein Brand 13 $946
Oxycodone Hcl Generic 52 $824
Pantoprazole Sodium Generic 36 $446
Ondansetron Hcl Generic 14 $224
Ondansetron Odt Ondansetron Brand 17 $220
Gabapentin Generic 21 $209

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$27,751

Medicare's payments for the services billed

Medicare patients

86

Average age 71

Services billed

382

40 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 48%
Cancer 40%
Ischemic heart disease 38%
Diabetes 37%
Chronic kidney disease 34%
Depression 33%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OGSIVEO
  • SpringWorks Therapeutics, Inc. $5,054
$5,054 — —
QINLOCK
  • Deciphera Pharmaceuticals Inc. $5,028
$5,028 — —
Fyarro
  • Aadi Bioscience, Inc. $517
$517 — —
Vanflyta
  • Daiichi Sankyo Inc. $211
$211 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record